You're right. No small company would ever forward their sole drug candidate from phase I if they had any inkling of any future issues.
Also, I've said repeatedly that I'm curious *if* it will occur. I didn't say it was a verified issue. If we can't ask questions about companies and their technology, then what's the point? TIA
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.